No clinical data released; watch for initial safety and efficacy readouts from this Phase 2 DMD trial, which could serve as a catalyst. The company's near-term value driver remains elritercept data in MDS/myelofibrosis.
Price Chart
Executive Summary
Keros Therapeutics announced the first patient dosed in a Phase 2 clinical trial of rinvatercept for Duchenne muscular dystrophy (DMD). This is an early operational milestone with no clinical data yet, making it a routine pipeline progress event for a clinical-stage biotech.
Key Facts
- First patient dosed in Phase 2 open-label, multi-cohort basket trial of rinvatercept in DMD (NCT07704099)
- Primary objective: safety and tolerability in late-ambulatory and early non-ambulatory DMD patients
- Secondary objectives: pharmacokinetics, anti-drug antibodies, body composition, and functional improvements (skeletal muscle, motor, cardiac, pulmonary)
- Rinvatercept is a ligand trap targeting myostatin and activin A, also being developed for ALS
- Elritercept is Keros' most advanced candidate, for cytopenias in MDS and myelofibrosis
Financial Impact
No financial data disclosed; pre-revenue clinical-stage company
Risk Factors
- Phase 2 trial may fail to meet safety or efficacy endpoints
- DMD is a competitive landscape with approved therapies and other pipeline candidates
- Keros has no approved products and relies on future funding for continued operations
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3369820 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | 8-K | $11.19 $11.40 | ▲ +1.88% | ▲ +2.08% | $11.33 (+1.25%) |
Sep 28, 2026 28d ago | 8-K | $11.28 $11.19 | ▼ −0.80% | ▼ −0.61% | $11.33 (+0.44%) |
Sep 28, 2026 28d ago | Press Release | $11.28 $11.19 | ▼ −0.80% | ▼ −0.61% | $11.33 (+0.44%) |
Sep 17, 2026 5w ago | EFFECT | $11.36 $11.19 | ▼ −1.50% | ▼ −1.38% | $11.33 (−0.26%) |
Sep 8, 2026 6w ago | 8-K | $11.31 $11.17 | ▼ −1.24% | ▼ −0.64% | $11.33 (+0.18%) |
Aug 20, 2026 9w ago | Insider Cluster | $11.03 $10.78 | ▼ −2.27% | ▼ −1.97% | $11.33 (+2.72%) |
Aug 3, 2026 12w ago | 8-K | $10.25 $10.00 | ▼ −2.49% | ▼ −2.29% | $11.33 (+10.54%) |
Aug 3, 2026 12w ago | Press Release | $10.25 $10.00 | ▼ −2.49% | ▼ −2.29% | $11.33 (+10.54%) |
Jul 30, 2026 12w ago | 8-K | $10.07 $10.11 | ▲ +0.40% | ▼ −1.03% | $11.33 (+12.51%) |
Jul 22, 2026 13w ago | 8-K | $10.14 $10.06 | ▼ −0.79% | ▼ −0.89% | $11.33 (+11.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers